DrugInfoSys

Pioglitazone

Drug #1644

Pioglitazone is a thiazolidinedione antidiabetic, reduces peripheral insulin resistance resulting in a reduction in blood-glucose concentration. Pioglitazone is used, either alone or in combination with metformin or sulphonylureas for the management of type II diabetes mellitus.

← Previous drugNext drug →

Primary Characteristics

Pioglitazone is also known as Pioglitazone HCL.

It is of Synthetic origin and belongs to Thiazolidinedione.

Non-proprietary name: Pioglitazone.

Molecular structure of Pioglitazone

Pharmacokinetics

Distribution: Pioglitazone has a volume of distribution is 0.63(0.22-1.04)l/kg. plasma protein binding is >99%.

Elimination: plasma half-life is 3-7 hrs, renal excretion is negligible.

Advertisement

Indications

Pioglitazone is primarily indicated in conditions like Diabetes mellitus type-ii, Softening and dilatation of cervix before mechanical cervical dilatation, Type II diabetes mellitus.

Contraindications

Pioglitazone is contraindicated in conditions like Cardiac failure, Hepatic impairment, Hypersensitivity to the drug, In combination with insulin, History of cardiac failure.

Dosage

Pioglitazone's dosage details are as follows:

DoseSingle DoseFrequencyRouteInstructions
Adult Dosage
22.5 mg22.5 mgEvery 24hPOIncreased according to response to 45 mg once daily.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown17 interactions
1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Pioglitazone in overdosage may give rise to further complications which include Jaundice .

Pioglitazone is known to cause more or less tolerable side effects which are usually transient. These include Headache, Myalgia, Pharyngitis, Sinusitis .

Warnings / Precautions

Monitor liver function (Rare reports of liver dysfunction; monitor liver function before treatment, then every 2 months for 12 months and periodically thereafter; ask patient to immediately get medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue and dark urine develop; discontinue if jaundice occurs. Cardiovascular disease (risk of heart failure)

Interference in Pathology

Pioglitazone may interfere in the diagnosis of Hematocrit Value , Elevaions in creatinine phosphokinase levels.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs
15 mg30 mg45 mg

Multi-Ingredient Combinations

Tabs
15 mg2 mg30 mg400 mg

Drug Classification

  1. 1.18.7.2 — Oral hypoglycemics

Manufacturers